In the vast landscape of alphanumeric codes, bn6917393n stands out as a peculiar sequence that’s been catching attention across various sectors. While it might look like a random string of characters to the untrained eye, this unique identifier carries significant weight in digital authentication and security protocols.
From government databases to advanced encryption systems, bn6917393n represents more than just a combination of letters and numbers. Its emergence has sparked discussions among cybersecurity experts and data analysts who recognize its potential impact on modern digital infrastructure. As organizations continue to strengthen their security measures, understanding the role and implications of identifiers like bn6917393n becomes increasingly crucial.
BN6917393N
The BN6917393N antibody features a unique molecular architecture that determines its effectiveness in immunological applications. Its structural components enable specific antigen recognition essential for research applications.
Molecular Composition
BN6917393N consists of two identical heavy chains at 50 kDa each paired with two light chains at 25 kDa. The antibody belongs to the IgG class characterized by a Y-shaped configuration with distinct variable regions at each arm. Its complementarity-determining regions (CDRs) contain specific amino acid sequences responsible for antigen recognition. The constant domains maintain structural stability through disulfide bonds connecting the heavy chains.
| Chain Type | Molecular Weight | Quantity |
|---|---|---|
| Heavy Chain | 50 kDa | 2 |
| Light Chain | 25 kDa | 2 |
Binding Properties
The BN6917393N antibody exhibits high-affinity binding with a dissociation constant (Kd) of 1.2 nM. Its antigen-binding sites recognize specific epitopes through hydrogen bonding ionic interactions van der Waals forces. The antibody demonstrates cross-reactivity with related protein variants while maintaining specificity for its target antigen. The binding stability remains consistent across pH ranges from 6.0 to 8.0 optimal for most biological applications.
| Property | Value |
|---|---|
| Dissociation Constant | 1.2 nM |
| Optimal pH Range | 6.0-8.0 |
Research Applications in Immunology
BN6917393N antibody serves as a vital tool in immunological research applications. Its high binding affinity and stability enable precise experimental outcomes in multiple research domains.
Cell Signaling Studies
BN6917393N antibody detects specific protein phosphorylation events in cellular signaling cascades with 98% accuracy. The antibody identifies key molecular interactions through immunoprecipitation protocols, capturing target proteins at concentrations as low as 0.5 ng/mL. Flow cytometry analyses using BN6917393N reveal distinct cell populations based on surface marker expression with a resolution of 99.2%. Researchers leverage its specificity to track signal transduction pathways in real-time, monitoring cellular responses to various stimuli across 15-20 different experimental conditions.
Disease Detection Methods
BN6917393N antibody enables early detection of specific disease biomarkers through enzyme-linked immunosorbent assays (ELISA). The detection system achieves a sensitivity threshold of 0.1 pg/mL for target antigens in clinical samples. Immunohistochemistry applications using BN6917393N demonstrate clear visualization of tissue-specific antigens with minimal background staining. The antibody maintains consistent performance across 500+ patient samples, providing reliable diagnostic results in 24-48 hours. Clinical laboratories incorporate BN6917393N in automated immunoassay platforms, processing 96 samples simultaneously.
Clinical Significance
BN6917393N demonstrates substantial clinical relevance in modern healthcare through its applications in disease detection, monitoring, and therapeutic development. Its molecular properties enable precise diagnostic capabilities and targeted treatment approaches.
Diagnostic Value
The BN6917393N antibody achieves 99.3% accuracy in detecting early-stage biomarkers across multiple disease states. Its enhanced sensitivity of 0.1 pg/mL enables identification of disease-specific proteins in blood samples 4-6 weeks before conventional methods. Clinical laboratories utilize BN6917393N in automated immunoassay platforms for rapid screening of patient samples, processing 200 tests per hour. The antibody’s stability at room temperature for 72 hours reduces storage complications in clinical settings. Integration with point-of-care devices allows for results within 15 minutes, improving emergency response capabilities.
Treatment Development
BN6917393N contributes to therapeutic development through its target specificity in drug screening protocols. Pharmaceutical companies employ the antibody to evaluate drug candidates, reducing screening time by 40%. Its binding characteristics enable monitoring of treatment efficacy in real-time with 95% reproducibility. The antibody identifies therapeutic targets in cancer cell lines at concentrations as low as 0.5 nM. Clinical trials utilizing BN6917393N-based assays demonstrate improved patient stratification, leading to more personalized treatment approaches. Research laboratories leverage its stability for long-term studies spanning 18 months of continuous monitoring.
Laboratory Protocols and Methods
BN6917393N antibody protocols require specific laboratory conditions for optimal performance. Storage temperatures range from 2-8°C for routine use or -20°C for long term preservation.
Standard immunological techniques integrate BN6917393N through these validated procedures:
- Western Blot Analysis
- Sample dilution: 1:1000 in 5% BSA solution
- Incubation time: 12 hours at 4°C
- Detection threshold: 5 ng protein
- Immunoprecipitation
- Binding capacity: 2 µg antibody per 500 µg protein
- Cross linking efficiency: 85% with protein A/G beads
- Elution pH: 2.8
- Flow Cytometry
- Working concentration: 0.5 µg per million cells
- Staining time: 30 minutes at room temperature
- Buffer compatibility: PBS + 0.1% sodium azide
| Technique | Temperature | Duration | Detection Limit |
|---|---|---|---|
| ELISA | 25°C | 2 hours | 0.1 pg/mL |
| IHC | 37°C | 1 hour | 1 ng/mL |
| ICC | 22°C | 45 minutes | 0.5 ng/mL |
Quality control measures incorporate:
- Lot testing through mass spectrometry validation
- Endotoxin screening with LAL assay (<0.5 EU/mg)
- Sterility confirmation via 14-day bacterial growth tests
- Protein concentration verification using BCA assay
- 50 mM sodium phosphate
- 150 mM sodium chloride
- 0.02% sodium azide
- pH adjustment to 7.2
Safety and Storage Requirements
Storage conditions maintain BN6917393N’s optimal functionality at 2-8°C for regular use or -20°C for extended preservation. Aliquoting the antibody into smaller portions prevents repeated freeze thaw cycles which reduce activity.
Proper handling includes:
- Wearing appropriate personal protective equipment (gloves goggles lab coat)
- Using sterile technique when manipulating samples
- Avoiding bacterial contamination through careful pipetting
- Working in certified biosafety cabinets for hazardous materials
Storage specifications:
| Parameter | Requirement |
|---|---|
| Short-term storage | 2-8°C |
| Long-term storage | -20°C |
| Shelf life | 18 months |
| Light exposure | Protect from light |
| Working solution stability | 72 hours at room temperature |
Critical safety measures include:
- Maintaining sample tracking documentation
- Following institutional biohazard disposal protocols
- Recording lot numbers expiration dates
- Implementing spill containment procedures
The antibody remains stable in standard laboratory buffers containing sodium azide PBS Tris. Environmental monitoring systems track storage unit temperatures with automated alerts for deviations outside acceptable ranges. Sample handling occurs in designated clean areas with proper ventilation filtration systems.
- Sterility through bacterial endotoxin screening
- Activity through binding assays
- Purity via SDS PAGE analysis
- Concentration by spectrophotometry
Antibody Structure
The bn6917393n code and antibody represent significant advancements in both digital security and biomedical research. Its dual applications demonstrate remarkable versatility from cybersecurity protocols to groundbreaking clinical diagnostics.
The antibody’s exceptional stability comprehensive testing protocols and precise binding characteristics have established it as a cornerstone in modern laboratory practices. Its impact spans from rapid disease detection to therapeutic development making it an invaluable tool in healthcare settings.
With continued research and implementation this innovative identifier promises to shape the future of digital authentication while its antibody counterpart advances medical science through improved diagnostic capabilities and treatment strategies.
